With so many changes in how people communicate, the lead generation and conversion process seems daunting. But experts say ...
Armed with new proof-of-concept data showing that its in vivo base-editing therapy BEAM-302 can correct the gene mutation in alpha-1 antitrypsin deficiency (AATD), Beam Therapeutics is seeking to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results